Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216892
Status:
COMPLETED
Last Update Posted:
2015-03-26
First Post:
2005-09-15
Brief Title:
Efficacy and Safety of Calcipotriol Cream and Calcipotriol Betamethasone Dipropionate Ointment in Psoriasis Vulgaris
Sponsor:
LEO Pharma
Organization:
LEO Pharma
Study Overview
Official Title:
Different Treatment Regimens of Calcipotriol Cream and Combination CalcipotriolBetamethasone Dipropionate Ointment in Psoriasis Vulgaris
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with psoriasis vulgaris of the trunk andor limbs are randomised to treatment with
1 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream
2 4 weeks of calcipotriol plus betamethasone dipropionate ointment followed by 8 weeks of calcipotriol cream on weekdays calcipotriol plus betamethasone dipropionate ointment on weekends
3 4 weeks of calcipotriol plus betamethasone dipropionate ointment followed by 8 weeks of vehicle of calcipotriol cream
The objective is to compare the efficacy and safety of the different treatment regimens
1 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream
2 4 weeks of calcipotriol plus betamethasone dipropionate ointment followed by 8 weeks of calcipotriol cream on weekdays calcipotriol plus betamethasone dipropionate ointment on weekends
3 4 weeks of calcipotriol plus betamethasone dipropionate ointment followed by 8 weeks of vehicle of calcipotriol cream
The objective is to compare the efficacy and safety of the different treatment regimens
Detailed Description:
A phase IV study of different treatment regimens of calcipotriol 50 mcgg cream and combination calcipotriol 50 mcgg plus betamethasone 05 mgg as dipropionate ointment following treatment with combination ointment in psoriasis vulgaris
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None